- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00656825
Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers
Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Three different formulations of DIGNA P144 cream (containing 100 μg/mL, 200 μg/mL and 300 μg/mL) will be tested in healthy volunteers. Tolerability evaluation is performed through the specific cutaneous tolerability visual scale of Frosch and Kligman. Safety assessment is carried out by studying vital signs, physical examination, by performing laboratory tests, electrocardiogram and reporting any adverse events experienced. This is the first time that P144 will be administered in humans. The topical route has been chosen since the indication for which P144 is going to be clinically developed will be cutaneous sclerosis associated to scleroderma.
Systemic sclerosis or scleroderma is a multisystemic disorder characterized by the excessive synthesis and deposition of extracellular matrix proteins that result in the fibrosis of skin and visceral organs (including gastrointestinal tract, lungs, heart and kidneys).
The pathogenesis of scleroderma is complex and still poorly understood, but major pathways involved in the development of the condition are microvascular and immunological abnormalities, as well as dysregulation of fibroblast activity. One of the key molecules involved in the pathogenesis of skin fibrosis is the TGF-β1; TGF-β1 is a cytokine directly responsible for fibroblasts proliferation and collagen and extracellular matrix overproduction.
The affected skin of patients with systemic sclerosis gradually becomes firm, thickened and eventually tightly bound to underlying subcutaneous tissue (indurative phase). It loses hair, oil, and sweat glands becoming dry and coarse. Changes begin distally in the extremities and advance proximally. Lesions develop over a period of time varying from months to a few years. In patients with limited scleroderma, only the skin of fingers, hands, face and lower arms and legs is affected. On the contrary, patients with the diffuse cutaneous disease, skin changes will become generalized, involving initially the extremities and followed by the face and trunk. Rapid progression of these changes over a 2 to 3 year period is usually associated with a greater risk of visceral disease. After several years of disease, the skin may soften and return to normal thickness or become thin and atrophic.
There is currently no approved specific treatment for skin fibrosis in systemic sclerosis neither in the European Union nor the United States of America. P144 belongs to a peptide family that is able to inhibit TGF-β1 in both in vitro and in vivo models characterized by excessive TGF-β1 function. Topical application of P144 exerts a preventive effect precluding the induction of skin fibrosis and the accumulation of collagen in these animals and also has shown its therapeutic properties reducing the skin fibrosis and soluble collagen content in mice with established fibrosis.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28035
- Hospital Universitario Puerta de Hierro
-
Pamplona, Spain, 31008
- Clinica Universitaria de Navarra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed.
- Age between 18 and 45 years old
- Skin phenotype I to IV following Fitzpatrick's classification scale
- BMI between 20-29 kg/sqm
- Not clinically relevant alterations in: arterial pressure, cardiac frequency, analytical values (Hematology, Biochemistry, Urianalysis, Coagulation, Serology, Toxics)
Exclusion Criteria:
- Pregnany or lactancy
- Allergy to any medication
- Subjects with skin illnesses or systemic illnesses with skin afectation
- History of drug abuse or regular consumption of alcohol
- Participation in other clinical trials 3 months before the signature of the informed consent
- UV exposure or sun exposure on the zone to be treated
- History of skin hypersensitivity
- Chronic treatment with anti-inflammatories or anti-histaminics
- Treatment with corticoids on the previous month
- Hyperpigmentation on the zone to be treated
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Panel I
The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
|
P144 cream will be given at a dose of 100 μg/mL
P144 cream will be given at a dose of 200 μg/mL
P144 cream will be given at a dose of 300 μg/mL
|
Active Comparator: Panel II
The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
|
P144 cream will be given at a dose of 100 μg/mL
P144 cream will be given at a dose of 200 μg/mL
P144 cream will be given at a dose of 300 μg/mL
|
Active Comparator: Panel III
The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
|
P144 cream will be given at a dose of 100 μg/mL
P144 cream will be given at a dose of 200 μg/mL
P144 cream will be given at a dose of 300 μg/mL
|
Placebo Comparator: Placebo
Patients from each panel will be given placebo in a 4:8 ratio.
|
Placebo will be randomly given to 4 subjects in each panel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tolerability evaluation was performed through the specific cutaneous tolerability visual scale of Frosch and Kligman.
Time Frame: Twenty-one days
|
Twenty-one days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessment was carried out by studying vital signs, physical examination, by performing laboratory tests, electrocardiogram and reporting any adverse events experienced. Bioavailability of P 144 in serum.
Time Frame: Twenty-one days
|
Twenty-one days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Belén Ruiz, MD, Hospital Universitario Puerta de Hierro
- Principal Investigator: Belén Sádaba, MD, Clinica Universitaria de Navarra
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NAFB001-SS-01
- 2006-002755-33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on P144 cream
-
ISDINDigna Biotech S.L.CompletedSkin FibrosisUnited Kingdom, Spain, Italy, Poland, Germany, Hungary
-
ISDINDigna Biotech S.L.CompletedSkin FibrosisSpain, United Kingdom, Germany, Poland, Hungary, Italy
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Edesa Biotech Inc.JSS Medical Research Inc.Active, not recruitingAllergic Contact DermatitisUnited States, Canada
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
LEO PharmaCompletedHealthy VolunteersGermany
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States, Canada